Connection

Mark Rubinstein to CD8-Positive T-Lymphocytes

This is a "connection" page, showing publications Mark Rubinstein has written about CD8-Positive T-Lymphocytes.
Connection Strength

5.000
  1. Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers. J Immunol. 2022 03 15; 208(6):1362-1370.
    View in: PubMed
    Score: 0.689
  2. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
    View in: PubMed
    Score: 0.526
  3. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Ra Dependent. Cancer Immunol Res. 2015 Dec; 3(12):1364-74.
    View in: PubMed
    Score: 0.438
  4. IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells. Cancer Gene Ther. 2015 Jul; 22(7):360-7.
    View in: PubMed
    Score: 0.435
  5. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. 2015 May; 64(5):539-49.
    View in: PubMed
    Score: 0.423
  6. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
    View in: PubMed
    Score: 0.384
  7. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
    View in: PubMed
    Score: 0.344
  8. IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response. Blood. 2008 Nov 01; 112(9):3704-12.
    View in: PubMed
    Score: 0.269
  9. B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
    View in: PubMed
    Score: 0.170
  10. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells. Eur J Immunol. 2020 09; 50(9):1386-1399.
    View in: PubMed
    Score: 0.152
  11. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811.
    View in: PubMed
    Score: 0.117
  12. Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
    View in: PubMed
    Score: 0.117
  13. Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother. 2016 Mar; 65(3):247-59.
    View in: PubMed
    Score: 0.113
  14. IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
    View in: PubMed
    Score: 0.111
  15. The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
    View in: PubMed
    Score: 0.105
  16. Surviving the crash: transitioning from effector to memory CD8+ T cell. Semin Immunol. 2009 Apr; 21(2):92-8.
    View in: PubMed
    Score: 0.070
  17. The lymphopenic environment of CD132 (common gamma-chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol. 2008 Apr 15; 180(8):5320-6.
    View in: PubMed
    Score: 0.066
  18. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008 Apr 15; 68(8):2972-83.
    View in: PubMed
    Score: 0.066
  19. An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med. 2007 Aug 06; 204(8):1787-801.
    View in: PubMed
    Score: 0.063
  20. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
    View in: PubMed
    Score: 0.060
  21. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9166-71.
    View in: PubMed
    Score: 0.058
  22. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006 Mar 31; 311(5769):1924-7.
    View in: PubMed
    Score: 0.057
  23. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
    View in: PubMed
    Score: 0.050
  24. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Med. 2021 03; 10(5):1805-1814.
    View in: PubMed
    Score: 0.040
  25. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. 2015 Jun 01; 21(11):2546-57.
    View in: PubMed
    Score: 0.027
  26. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15; 73(10):3075-86.
    View in: PubMed
    Score: 0.023
  27. Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med. 2007 Apr 16; 204(4):951-61.
    View in: PubMed
    Score: 0.015
  28. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.